drugset
drugset / Trial / NCT03023592

Study of Iguratimod in Sjögren's Syndrome

NCT03023592 ↗

Phase 1/2 Unknown 30 enrolled Peking Union Medical College Hospital
NaSingle-groupOpen-labelTreatment

Summary

A single-center, self-control, open-label study of efficacy and safety of Iguratimod in patients with Sjögren's Syndrome

Timeline

Start
2017-02
Primary completion
2018-02
Completion
2018-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Iguratimod Small molecule 25 mg Oral

Indications

Sjogren syndrome